Laminaria japonica Aresch‐Derived Fucoidan Ameliorates Hyperlipidemia by Upregulating LXRs and Suppressing SREBPs
Cardiovascular Therapeutics · 2024-01 · 2024 (1)
DOI: 10.1155/2024/8649365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 12.02.2024. Verfasst von Yan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Guiqian International General Hospital, Guiyang 550018, China. Hauptthemen laut MEDLINE: Hyperlipidemias, Cardiovascular Diseases, Edible Seaweeds, Laminaria. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide, and hyperlipidemia is one major inducing factor of CVD. It is worthy to note that fucoidans are reported to have hypolipidemic activity with species specificity; however, the underlying mechanisms of action are far from clarification. This study is aimed at investigating the plasma lipid‐lowering mechanisms of the fucoidan from L. japonica Aresch by detecting the levels of hepatic genes that are involved in lipid metabolism. Our results demonstrated that the fucoidan F3 significantly lowered total cholesterol and triglyceride in C57BL/6J mice fed a high‐fat diet. In the mouse liver, fucoidan F3 intervention significantly increased the gene expression of peroxisome proliferator‐activated receptor (PPAR) α , liver X receptor (LXR) α and β , and ATP‐binding cassette transporter (ABC) G1 and G8 and decreased the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), low‐density lipoprotein receptor, cholesterol 7 alpha‐hydroxylase A1, and sterol regulatory element‐binding protein (SREBP) 1c and SREBP‐2. These results demonstrated that the antihyperlipidemic effects of fucoidan F3 are related to its activation of PPAR α and LXR/ABC signaling pathways and inactivation of SREBPs. In conclusion, fucoidan F3 may be explored as a potential compound for prevention or treatment of lipid disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Guiqian International General Hospital, Guiyang 550018, China.
- Institute of Lipid Metabolism and Atherosclerosis, Innovative Drug Research Centre, School of Pharmacy, Weifang Medical University, Weifang 261053, China.
- Cardiology Department, Qingzhou People's Hospital, Weifang 262500, China.
- Shandong Provincial Key Laboratory for Rheumatic Disease and Translational Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, China.
ORCID-Profile: Yan Zhang, Tian Liu, Ze-Jie Qu, Xue Wang, Wen-Gang Song, Shou-Dong Guo
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Liu, T., Qu, Z. J., Wang, X., Song, W. G., & Guo, S. D. (2024). Laminaria japonica Aresch‐Derived Fucoidan Ameliorates Hyperlipidemia by Upregulating LXRs and Suppressing SREBPs. Cardiovascular Therapeutics, 2024(1). https://doi.org/10.1155/2024/8649365
Vancouver
Zhang Y, Liu T, Qu ZJ, Wang X, Song WG, Guo SD. Laminaria japonica Aresch‐Derived Fucoidan Ameliorates Hyperlipidemia by Upregulating LXRs and Suppressing SREBPs. Cardiovascular Therapeutics. 2024;2024(1). doi:10.1155/2024/8649365
BibTeX
@article{Zhang2024,
author = {Zhang, Yan and Liu, Tian and Qu, Ze-Jie and Wang, Xue and Song, Wen-Gang and Guo, Shou-Dong},
title = {Laminaria japonica Aresch‐Derived Fucoidan Ameliorates Hyperlipidemia by Upregulating LXRs and Suppressing SREBPs},
journal = {Cardiovascular Therapeutics},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/2024/8649365}
}
EUVIMED